Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. 4D Molecular Therapeutics Inc’s current trading price is -64.37% away from its 52-week high, while its distance from the 52-week low is 187.25%. The stock’s price range during this period has varied between $2.23 and $18.02. The company, active in the Healthcare sector, saw a trading volume of around 31.4 million for the day, considerably higher average daily volume of 0.45 million observed over the last three months.
Currently, the stock price of 4D Molecular Therapeutics Inc (FDMT) is $6.42. In the most recent trading session, the stock underwent a significant upswing, peaking at $45.0 after opening at $6.42. The stock touched a low of $10.0 before closing at $4.5.
The stock market performance of 4D Molecular Therapeutics Inc has been very steady.
How Financial Performance Impacts Market Capitalization
4D Molecular Therapeutics Inc (FDMT) has experienced a quarterly rise of 86.63% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 297.40M and boasts a workforce of 227 employees.
Decoding Analysts’ Ratings for 4D Molecular Therapeutics Inc
As of right now, 5 analysts are rating 4D Molecular Therapeutics Inc as a BUY, 4 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.78, with a change in price of +2.53. Similarly, 4D Molecular Therapeutics Inc recorded 859,062 in trading volume during the last 100 days, posting a change of +64.83%.
How FDMT’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for FDMT stands at 0.05. Similarly, the long-term debt-to-equity ratio is also 0.04.
FDMT Stock Stochastic Average
As of today, the raw stochastic average of 4D Molecular Therapeutics Inc over the last 50 days is at 91.88%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 90.46%. Further, the company’s Stochastic %K and %D values for the last 20 days were 72.35% and 67.70%, respectively.
FDMT Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. This year’s metric has recorded a Price decrease of -62.59%. However, over the past six months, we’ve seen a weaker performance of 14.64%. The price of FDMT fallen by 48.96% over the last 30 days. And in the last five days, it has surged by 40.48%.
